ValuEngine cut shares of Vermillion, Inc. (NASDAQ:VRML) from a hold rating to a sell rating in a research note issued to investors on Wednesday.

Separately, Canaccord Genuity boosted their target price on Vermillion from $1.75 to $2.25 and gave the stock a buy rating in a report on Thursday, November 2nd.

Vermillion (NASDAQ:VRML) opened at $1.39 on Wednesday. The company has a quick ratio of 3.67, a current ratio of 3.74 and a debt-to-equity ratio of 0.26. Vermillion has a 52 week low of $0.91 and a 52 week high of $2.85.

Vermillion (NASDAQ:VRML) last issued its earnings results on Wednesday, November 8th. The company reported ($0.06) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.04) by ($0.02). The company had revenue of $0.70 million during the quarter. Vermillion had a negative net margin of 332.10% and a negative return on equity of 200.44%.

COPYRIGHT VIOLATION NOTICE: “ValuEngine Lowers Vermillion, Inc. (VRML) to Sell” was first reported by Watch List News and is the property of of Watch List News. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at

A number of large investors have recently made changes to their positions in VRML. Essex Investment Management Co. LLC raised its stake in Vermillion by 145.8% during the 3rd quarter. Essex Investment Management Co. LLC now owns 216,607 shares of the company’s stock valued at $390,000 after purchasing an additional 128,494 shares during the period. Vanguard Group Inc. boosted its holdings in Vermillion by 0.7% in the second quarter. Vanguard Group Inc. now owns 580,484 shares of the company’s stock worth $1,068,000 after purchasing an additional 4,200 shares in the last quarter. Finally, Birchview Capital LP boosted its holdings in Vermillion by 7.9% in the third quarter. Birchview Capital LP now owns 2,462,933 shares of the company’s stock worth $4,433,000 after purchasing an additional 180,000 shares in the last quarter. 33.79% of the stock is currently owned by institutional investors.

Vermillion Company Profile

Vermillion, Inc is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician’s clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Vermillion Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.